Fujifilm kicks off Humira biosim project; France sees spike in healthcare IPOs;

@FierceBiotech: Who thinks they've got the tonic for Big Pharma social media headaches? This guy does: Piece | Follow @FierceBiotech

@JohnCFierce: VC boom: U.K. charity births $80M biotech fund for cancer drug research--I count $730M in new U.K./euro funds this month. Story | Follow @JohnCFierce

@RyanMFierce: Moscow backs clones of Western biotech programs in Russia. More | Follow @RyanMFierce

@FierceMedDev: Roche raises bid for U.S. diagnostics firm Illumina - San Jose Mercury News. Article | Follow @FierceMedDev

> Japan's Kyowa Hakko Kirin and Fujifilm have initiated their biosimilars joint venture, with an initial focus on Abbott's ($ABT) Humira. Story

> Seattle's Accelerator has tapped David McElligott as its new CSO. He replaces Patrick Gray, who took a position at Omeros. News

> Now that DBV Technologies has priced its shares, France has recorded its fourth healthcare IPO in the quarter, the most for any quarter in at least 20 years. Story

> Nile Therapeutics says its Phase I study for an experimental heart drug met its endpoint. Report

Pharma News

@FiercePharma: Who could make a play for Amylin next? AstraZeneca and Sanofi, per analysts. Bristol-Myers may return, too. Article | Follow @FiercePharma

> Allergan asks FDA for lucrative new Botox indication. Item

> Judge denies AZ's bid to stop Seroquel copies, but chides FDA. News

> Who's next to move on Amylin? Analysts say Big Pharma looms. Story

CRO News

> Parexel should see more revenue, higher share prices, analysts say. More

> Cetero sees strong future despite bankruptcy protection filing. Article

> INC Research axes staffers, closes Connecticut lab. Story

> Spaulding's hand-held ECG fuels tax credits and hiring boom. Item

> Report sheds light on pharma and CRO trial enrollment woes. News

Vaccines News

> Vaxfectin-based malaria vaccine could stop transmission. Item

> Narcolepsy spike linked with flu shot. Story

> Academics' oral stomach flu vax could save lives. Article

> Genetic tweaking could create chlamydia vaccine. More

Manufacturing News

> CMC, third-party manufacturing issues delay Map drug launch. News

> California implant makers get FDA warnings. Article

> Novartis plant disruptions affect pet treatments. Story

> Sandoz Canada president explains shortages to House of Commons. Article

> Halo agrees to buy Teva's Montreal facility. Report

And Finally… An international group of investigators is working on a new "micro-robot" designed to detect diseases. Release

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.